{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:12:25Z","timestamp":1773465145550,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Noninvasive detection of primary graft dysfunction (PGD) remains a major challenge. SERCA2a plays an important role in cardiac homeostasis and its dysregulation has been associated with ventricular dysfunction and rejection. This study aimed to determine the potential utility of plasma levels of SERCA2a as a biomarker of PGD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>One hundred thirty-five plasma samples were collected from adult recipients 2\u20136 hours before heart transplantation (HT). Plasma concentrations of SERCA2a were determined using a specific sandwich ELISA. Variables related to the recipient, the donor, and the periprocedural were collected to determine a multivariate predictive model of PGD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Levels of SERCA2a were decreased in patients who developed PGD (median 0.430 ng\/mL [interquartile range, 0.260\u20130.945] versus 0.830 ng\/mL [interquartile range, 0.582\u20131.052]; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001). Receiver operating characteristic curve analysis revealed that SERCA2a discriminated between patients with and without PGD (AUC = 0.682; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001), and a cutoff point \u2265 0.60 ng\/mL was a protective independent predictor of PGD (odds ratio 0.215 [<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004]). Three independent predictors of PGD in this study were reduced levels of pre-HT SERCA2a, increased bilirubin levels, and short-term mechanical circulatory support bridge to transplantation. The analysis of the receiver operating characteristic curve of the model obtained a significant AUC 0.788, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Our findings suggest that assessment of SERCA2a plasma levels may improve risk prediction for the occurrence of PGD and could be considered as a novel noninvasive biomarker in patients undergoing HT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003798","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T03:17:57Z","timestamp":1619493477000},"page":"887-893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Plasma Levels of SERCA2a as a Noninvasive Biomarker of Primary Graft Dysfunction After Heart Transplantation"],"prefix":"10.1097","volume":"106","author":[{"given":"Silvia","family":"Lozano-Edo","sequence":"first","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"S\u00e1nchez-L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Portol\u00e9s","sequence":"additional","affiliation":[{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Rosell\u00f3-Llet\u00ed","sequence":"additional","affiliation":[{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefania","family":"Taraz\u00f3n","sequence":"additional","affiliation":[{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Arnau-Vives","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Ezzitouny","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Lopez-Vilella","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Almenar-Bonet","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mart\u00ednez-Dolz","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Valencia, Spain."},{"name":"Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain."},{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red, M.P (CIBERCV), Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.healun.2015.08.003","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirty-second Official Adult Heart Transplantation Report\u20132015; Focus Theme: early graft failure.","volume":"34","author":"Lund","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.healun.2014.02.027","article-title":"Report from a consensus conference on primary graft dysfunction after cardiac transplantation.","volume":"33","author":"Kobashigawa","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/TP.0b013e3181e6f1eb","article-title":"Factors associated with primary graft failure after heart transplantation.","volume":"90","author":"Russo","year":"2010","journal-title":"Transplantation"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.healun.2011.01.721","article-title":"RADIAL: a novel primary graft failure risk score in heart transplantation.","volume":"30","author":"Segovia","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/ajt.14588","article-title":"Primary graft dysfunction after heart transplantation: incidence, trends, and associated risk factors.","volume":"18","author":"Nicoara","year":"2018","journal-title":"Am J Transplant"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.healun.2017.02.014","article-title":"Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: epidemiology, risk factors, and outcomes.","volume":"36","author":"Sabatino","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R7-20250607","first-page":"263","article-title":"Application of the International Society for Heart and Lung Transplantation (ISHLT) criteria for primary graft dysfunction after cardiac transplantation: outcomes from a high-volume centre\u2020.","volume":"51","author":"Squiers","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cardfail.2019.07.009","article-title":"PREDICTA: a model to predict primary graft dysfunction after adult heart transplantation in the United Kingdom.","volume":"25","author":"Avtaar Singh","year":"2019","journal-title":"J Card Fail"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.healun.2017.05.026","article-title":"Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation.","volume":"36","author":"Agbor-Enoh","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCRESAHA.113.302187","article-title":"Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later.","volume":"113","author":"Eisner","year":"2013","journal-title":"Circ Res"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5483\/BMBRep.2013.46.5.077","article-title":"SERCA2a: a prime target for modulation of cardiac contractility during heart failure.","volume":"46","author":"Park","year":"2013","journal-title":"BMB Rep"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1600-6143.2006.01241.x","article-title":"Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression.","volume":"6","author":"St\u00fcdeli","year":"2006","journal-title":"Am J Transplant"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.healun.2017.07.003","article-title":"SERCA2a: a potential non-invasive biomarker of cardiac allograft rejection.","volume":"36","author":"Taraz\u00f3n","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","article-title":"Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure.","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ Res"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1513\/pats.200701-011GC","article-title":"The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials.","volume":"4","author":"Macrae","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jacc.2020.11.044","article-title":"Etiology-dependent impairment of diastolic cardiomyocyte calcium homeostasis in heart failure with preserved ejection fraction.","volume":"77","author":"Frisk","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.transproceed.2010.05.139","article-title":"Impact of overweight on survival and primary graft failure after heart transplantation.","volume":"42","author":"Guisado Rasco","year":"2010","journal-title":"Transplant Proc"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.clinre.2018.03.006","article-title":"Predictive value of liver damage for severe early complications and survival after heart transplantation: a retrospective analysis.","volume":"42","author":"Lebray","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.hlc.2014.04.259","article-title":"Normalisation of haemodynamics in patients with end-stage heart failure with continuous-flow left ventricular assist device therapy.","volume":"23","author":"Gupta","year":"2014","journal-title":"Heart Lung Circ"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.healun.2017.05.025","article-title":"Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation.","volume":"36","author":"Wright","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.healun.2018.07.013","article-title":"Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices.","volume":"37","author":"Truby","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.healun.2018.03.009","article-title":"Donor predicted heart mass as predictor of primary graft dysfunction.","volume":"37","author":"Gong","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.healun.2018.01.894","article-title":"Primary graft failure is more common in patients bridged to heart transplant with LVAD: role of early peripheral ECMO.","volume":"37","author":"Tea","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10741-019-09794-1","article-title":"Primary graft dysfunction after heart transplantation: a thorn amongst the roses.","volume":"24","author":"Singh","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"e002909","DOI":"10.1161\/CIRCHEARTFAILURE.115.002909","article-title":"Donor troponin and survival after cardiac transplantation: an analysis of the United Network of Organ Sharing Registry.","volume":"9","author":"Madan","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.healun.2012.02.009","article-title":"Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation.","volume":"31","author":"Vorlat","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.healun.2018.01.038","article-title":"Pre-transplant serum exosome proteomics differentiates right and left ventricular primary graft dysfunction.","volume":"37","author":"Fine","year":"2018","journal-title":"J Heart Lung Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:09:15Z","timestamp":1749312555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003798","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}